OB/GYN Clinical Alert – January 1, 2024
January 1, 2024
View Archives Issues
-
Oral Contraception and Obesity
This study was a re-analysis of drospirenone 4 mg Phase III efficacy trials comparing 590 non-obese and 325 obese patients who showed equivalent pregnancy rates with Pearl Indices of 3.0 (95% confidence interval [CI], 1.3 to 5.8) and 2.9 (95% CI, 0.8 to 7.3), respectively.
-
Metformin for the Management of Early Gestational Diabetes
The administration of metformin in the early stages of gestational diabetes did not demonstrate superiority over placebo in relation to the need to start insulin therapy prior to delivery, or on fasting blood glucose concentrations ≥ 5.1 mmol/L at either the 32nd or 38th weeks of gestation (composite primary outcome).
-
Variables Associated with Resolution and Persistence of Ovarian Cysts
This prospective cohort study evaluated 2,683 individuals with incidental cysts discovered during ovarian cancer screenings to determine what factors are associated with cyst resolution over time. Characteristics such as smaller cysts, septated cysts, younger age, premenopausal status, and family history of ovarian cancer were associated with an increased percentage of cyst resolution overall, and factors including older age and lack of hormone therapy were associated with a faster rate of cyst resolution over time. The findings of this study indicate that different surveillance times may be appropriate, depending on cyst morphology and patient characteristics.
-
Malaria in Pregnancy — Simplified Treatment Decisions
History, data, and international consensus lead to the same conclusion: Artemether-lumefantrine is the first choice for treatment of uncomplicated falciparum malaria in everyone, even pregnant women.